Flexion Therapeutics Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Flexion Therapeutics stock.
View analyst ratings for Flexion Therapeutics or view top-rated stocks.

Wall Street analysts have given Flexion Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Flexion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Flexion Therapeutics.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its quarterly earnings data on Wednesday, November, 4th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01. The specialty pharmaceutical company earned $23.66 million during the quarter, compared to the consensus estimate of $23.59 million.
View Flexion Therapeutics' earnings history.

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FLXN shares have decreased by 10.5% and is now trading at $11.02.
View which stocks have been most impacted by COVID-19.

Flexion Therapeutics updated its FY 2020 Pre-Market earnings guidance on Wednesday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $85.5-85.5 million, compared to the consensus revenue estimate of $84.88 million.

12 equities research analysts have issued 1-year price objectives for Flexion Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they anticipate Flexion Therapeutics' stock price to reach $20.25 in the next year. This suggests a possible upside of 83.8% from the stock's current price.
View analysts' price targets for Flexion Therapeutics or view top-rated stocks among Wall Street analysts.

46 employees have rated Flexion Therapeutics CEO Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among Flexion Therapeutics' employees.

Some companies that are related to Flexion Therapeutics include Prestige Consumer Healthcare (PBH), Myovant Sciences (MYOV), Dicerna Pharmaceuticals (DRNA), Harmony Biosciences (HRMY), Stoke Therapeutics (STOK), Generation Bio (GBIO), Madrigal Pharmaceuticals (MDGL), NGM Biopharmaceuticals (NGM), ADC Therapeutics (ADCT), Endo International (ENDP), Aurinia Pharmaceuticals (AUPH), Pandion Therapeutics (PAND), Revance Therapeutics (RVNC), Seres Therapeutics (MCRB) and Shattuck Labs (STTK).
View all of FLXN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.80%), Artisan Partners Limited Partnership (6.24%), Orbimed Advisors LLC (4.68%), Schroder Investment Management Group (1.30%), Royce & Associates LP (1.27%) and Northern Trust Corp (1.09%). Company insiders that own Flexion Therapeutics stock include Adam Muzikant, C Ann Merrifield, David Arkowitz, Mark S Levine, Mark Stejbach, Melissa Layman, Michael D Clayman and Samuel D Colella.
View institutional ownership trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Squarepoint Ops LLC, Peregrine Capital Management LLC, Northern Trust Corp, Monarch Partners Asset Management LLC, Brandywine Global Investment Management LLC, and Dupont Capital Management Corp. Company insiders that have sold Flexion Therapeutics company stock in the last year include Adam Muzikant, David Arkowitz, Mark S Levine, and Melissa Layman.
View insider buying and selling activity for Flexion Therapeutics or view top insider-selling stocks.

FLXN stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Artisan Partners Limited Partnership, BlackRock Inc., Essex Investment Management Co. LLC, JPMorgan Chase & Co., Vontobel Holding Ltd., CM Management LLC, and New York State Common Retirement Fund. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Mark Stejbach, Michael D Clayman, and Samuel D Colella.
View insider buying and selling activity for Flexion Therapeutics or or view top insider-buying stocks.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLXN stock can currently be purchased for approximately $11.02.

Flexion Therapeutics has a market capitalization of $543.45 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis.

Flexion Therapeutics employs 288 workers across the globe.

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

Flexion Therapeutics is headquartered at 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]